The nuclear receptor PPARγ is a primary therapeutic target for insulin resistance and type 2 diabetes (T2D); however, its thiazolidinedione (TZD) class of PPARγ agonists have substantial safety concerns in clinical utilization. The gene discussed is PPARG; the disease is Insulin resistance.